期刊文献+

RP-HPLC法测定奥利司他片的含量 被引量:3

Content Determination of Orlistat Tablet by RP-HPLC Method
原文传递
导出
摘要 目的:建立奥利司他片的含量测定方法。方法:采用高效液相色谱法,Agela Venusil XBP-C18色谱柱(15cm×4.0mm,5μm),流动相:甲醇:水:甲酸(89:11:0.1);柱温为35℃;流速1.5mL.min-1;进样量10μL。紫外检测器,检测波长为210nm。结果:主成分奥利司他在0.40.6mg/ml浓度范围内线性关系良好,相关系数r〉0.999,平均回收率为99.4%,符合规定。结论:该方法专属性强,准确度好,可作为奥利司他片含量测定的质量控制方法。 Objective:A High performance liquid chromatography method was established to determine the contents of Orlistat Tablet.Methods:An isocratic separation was achieved by an Agela Venusil XBP-C18 C18 column at a flow rate of 1.5ml/min.The mobile phase consisted of methanol-water 89:11(v/v) spiked with 0.1 portion of formic acid.The UV detector was used at 210nm.Results:Complete separation was achieved for Orlistat and other impurities.The method was linear over the concentration range of 0.4~0.6mg/ml(r〉0.999) and the recoveries were accorded with prescribe.Conclusions:The HPLC method has the requisite accuracy and selectivity for the content determination of Orlistat Tablet.
出处 《现代生物医学进展》 CAS 2010年第22期4360-4362,共3页 Progress in Modern Biomedicine
基金 国家科技支撑计划生物医药领域课题资助项目(2008BAI67B04)
关键词 奥利司他片 高效液相色谱法 含量 Orlistat Tablet HPLC Content
  • 相关文献

参考文献4

二级参考文献22

  • 1[1]Eckel RH. Obesity and heart disease[J]. Circulation,1997,96(9) :3248 - 3250.
  • 2[2]Meigs J, Nathan D, Wilson P, et al. Metabolic risk factors worsencontinuously across the spectrum of nondiabetie glucose tolerance[J]. Ann Inter Med, 1998,28(7): 524 - 533.
  • 3[3]Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine [J]. N Engl JMed, 1997,337(9) :581 - 588.
  • 4[4]Stone NJ, Kushner R. Effects of dietary modification and treatment of obesity[J]. Med Clin North Am ,2000,84(1) :95 - 102.
  • 5[5]Xavier F,Sunyer PI,Laferrere B,et al. Obesity-a modern-day epidemic[J]. J Clin Endocrinol Metab, 1999,84 (1): 3 - 12.
  • 6[6]Sjostrom L, Rissanen A, Adersen T, et al. Randomised placebocontrolled trial of orlistat for weight loss and prevention of weightregain in obese patients[J]. Lancet, 1998, 352 (9123): 167 -173.
  • 7[7]Davidson MH, Hauptman J, DiGirolamo M. Weight control andrisk factors reduction in obese subjects treated for 2 years withorlistat[J]. JAMA, 1999,281(3):235 - 242.
  • 8[8]Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat,a lipase inhibitor,in healthy human volunteers[J]. J Clin Pharmacol, 1995,35 (11):1103 - 1198.
  • 9Schwartz TL, Beale M. Pharmacokinetics and drug interactions of the sedative hypnotics. Psychopharmacol Bull,2003,37 ( 1 ) :5.
  • 10Patrick K Bermett,Yu -Tsyir Li,Richard Edom,et al . Quantitative determination of orlistat ( Tetrahydrolipostatin, Ro 18 - 0647 ) in human plasma by high - performance liquid chromatography coupled with ionspray tandem mass spectrometry. J Mass Spectrom, 1997,32:739.

共引文献15

同被引文献29

  • 1杨小波,陈再新,张奕华.奥利司他的全合成研究进展[J].有机化学,2005,25(8):902-912. 被引量:4
  • 2肖松,朱小兰,陈波,姚守拙.高效液相色谱/质谱联用测定胶囊中奥利司他含量[J].药物分析杂志,2005,25(9):1055-1057. 被引量:5
  • 3许勇煌,彭韪,王德刚,等.一种奥利司他的制备方法:中国,201110047178[P].2011-02.28.
  • 4S.多斯沃德,E.库普弗,G.斯坦鲍尔,等.一制胰脂菌素的提纯方法:中国,00101172.3[P].2000-01-28.
  • 5朱健,陈晓霞.一种提纯奥利司他的方法:中国,200510094601.4[P].2005-09-29.
  • 6Keri Vilmos,Csorvasi Andrea,Aronhime Judith,et al.Preparation of orlistat and orlistat crystalline forms:US,6734314[P].2002-12-04.
  • 7Bapuso,Patil,Dattatray,et al.An improved process forthe preparation of orlistat:WO,2008/149321[P].2008-06-06.
  • 8Srinivas,Pullela,Venkata,et al.A process for obtainingtetrahydrolipstatin:WO,2009/040827[P].2007-11-13.
  • 9赵志全,刘茂田.一种生产制备奥利司他的方法:中国,201010505171.1[P].2010-10-13.
  • 10Sreekanth Nama,Babu Rao Chandu,Mukkanti Khagga.A new RP-HPLC method development and validation oforlistat in bulk and pharmaceutical dosage forms[J].IntJ Pharm Sci&Res,2010,1(6):251-257.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部